United States Biotechnology & Medical Research

Q32 Bio Inc (QTTB)

Track

In the last 90 days, Q32 Bio Inc. saw significant insider activity characterized by $30 million in total share purchases. Two major insiders, OrbiMed Advisors LLC and Xu Diyong, executed these buys on May 28, 2026. This follows a period of executive selling earlier in the year and a positive earnings report in May.
Ticker: QTTB Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Q32 Bio Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Xu Diyong
2 purchases — total 15,000,000 USD
Buy 28 May 2026
Value US$4,048,020.52 | Price 469.45 | Shares 22,388
Buy 28 May 2026
Value US$3,125,895.30 | Price 140.17 | Shares 3,658
Buy 28 May 2026
Value US$1,393,883.70 | Price 152.25 | Shares 7,673
Buy 28 May 2026
Value US$1,806,993.60 | Price 498.99 | Shares 21,495
Sale 25 Feb 2026
Value US$18,035.03 | Price 4.51 | Shares 3,995
Sale 25 Feb 2026
Value US$12,708.04 | Price 4.51 | Shares 2,815
Sale 25 Feb 2026
Value US$44,674.50 | Price 4.51 | Shares 9,896
Sale 2 Dec 2025
Value US$31,395.47 | Price 3.46 | Shares 9,072
Sale 2 Dec 2025
Value US$77,870.76 | Price 3.46 | Shares 22,506
Proposed sale 2 Dec 2025
Value US$77,870.76 | Price 3.46 | Shares 22,506
Proposed sale 2 Dec 2025
Value US$31,395.47 | Price 3.46 | Shares 9,072
Sale 26 Aug 2025
Value US$18,899.69 | Price 1.80 | Shares 10,494
Sale 26 Aug 2025
Value US$7,636.24 | Price 1.80 | Shares 4,240
Sale 26 Aug 2025
Value US$5,384.99 | Price 1.80 | Shares 2,990
Sale 25 Mar 2024
Value US$6,413.00 | Price 24.20 | Shares 265
Planned sale 25 Mar 2024
Value US$1,815.00 | Price 24.20 | Shares 75
Planned sale 25 Mar 2024
Value US$6,488.28 | Price 24.21 | Shares 268
Planned sale 9 Jan 2024
Value US$7,445.43 | Price 0.57 | Shares 13,037
Planned sale 3 Jan 2024
Value US$975.27 | Price 0.57 | Shares 1,708
Planned sale 3 Jan 2024
Value US$4,120.48 | Price 0.57 | Shares 7,280
Planned sale 6 Sep 2023
Value US$1,665.49 | Price 1.15 | Shares 1,448
Sale 3 Aug 2023
Value US$1,818.12 | Price 1.39 | Shares 1,308
Planned sale 3 Aug 2023
Value US$151.51 | Price 1.39 | Shares 109
Planned sale 3 Aug 2023
Value US$606.04 | Price 1.39 | Shares 436
Planned sale 2 Aug 2023
Value US$129.69 | Price 1.31 | Shares 99
Planned sale 2 Mar 2023
Value US$15,863.07 | Price 1.45 | Shares 10,965
Planned sale 9 Jan 2023
Value US$14,761.55 | Price 1.39 | Shares 10,616
Planned sale 9 Jan 2023
Value US$4,296.03 | Price 1.39 | Shares 3,090
Planned sale 9 Jan 2023
Value US$3,412.04 | Price 1.39 | Shares 2,454
Planned sale 9 Jan 2023
Value US$5,187.78 | Price 1.39 | Shares 3,729
Planned sale 9 Jan 2023
Value US$5,033.25 | Price 1.39 | Shares 3,620
Planned sale 5 Jan 2022
Value US$6,278.75 | Price 3.78 | Shares 1,661
Planned sale 5 Jan 2022
Value US$8,248.40 | Price 3.78 | Shares 2,182
Planned sale 5 Jan 2022
Value US$6,278.75 | Price 3.78 | Shares 1,661
Planned sale 5 Jan 2022
Value US$20,239.19 | Price 3.78 | Shares 5,354
Planned sale 5 Jan 2022
Value US$5,314.82 | Price 3.78 | Shares 1,406
Planned sale 8 Feb 2021
Value US$192,424.95 | Price 14.25 | Shares 13,500
Planned sale 2 Feb 2021
Value US$6,500.00 | Price 13.00 | Shares 500
Planned sale 1 Feb 2021
Value US$49,460.00 | Price 12.37 | Shares 4,000
Planned sale 12 Jan 2021
Value US$6,500.00 | Price 13.00 | Shares 500
Planned sale 7 Jan 2021
Value US$61,469.21 | Price 12.05 | Shares 5,103
Planned sale 6 Jan 2021
Value US$119,395.43 | Price 12.06 | Shares 9,897
Planned sale 5 Jan 2021
Value US$114,422.00 | Price 11.44 | Shares 10,000
Planned sale 4 Jan 2021
Value US$45,982.80 | Price 11.50 | Shares 4,000
Sale 22 Dec 2020
Value US$256,400.00 | Price 12.82 | Shares 20,000
Sale 22 Dec 2020
Value US$6,153,600.00 | Price 12.82 | Shares 480,000
Sale 22 Dec 2020
Value US$256,400.00 | Price 12.82 | Shares 20,000
Sale 22 Dec 2020
Value US$6,153,600.00 | Price 12.82 | Shares 480,000
Sale 14 Dec 2020
Value US$162,791.64 | Price 11.88 | Shares 13,703
Sale 14 Dec 2020
Value US$82,244.49 | Price 13.06 | Shares 6,297
Sale 14 Dec 2020
Value US$3,906,880.56 | Price 11.88 | Shares 328,862
Sale 14 Dec 2020
Value US$1,973,998.30 | Price 13.06 | Shares 151,138
Sale 14 Dec 2020
Value US$162,791.64 | Price 11.88 | Shares 13,703
Sale 14 Dec 2020
Value US$82,244.49 | Price 13.06 | Shares 6,297
Sale 14 Dec 2020
Value US$3,906,880.56 | Price 11.88 | Shares 328,862
Sale 14 Dec 2020
Value US$1,973,998.30 | Price 13.06 | Shares 151,138
Planned sale 17 Mar 2020
Value US$17,108.54 | Price 13.01 | Shares 1,315
Planned sale 3 Feb 2020
Value US$202,021.25 | Price 16.16 | Shares 12,500
Planned sale 3 Feb 2020
Value US$193,866.00 | Price 16.16 | Shares 12,000
Sale 30 Jan 2020
Value US$7,879,036.50 | Price 15.45 | Shares 509,970
Sale 29 Jan 2020
Value US$136,807.88 | Price 15.45 | Shares 8,857
Sale 28 Jan 2020
Value US$1,021,936.46 | Price 15.51 | Shares 65,891
Sale 27 Jan 2020
Value US$3,049,600.14 | Price 15.77 | Shares 193,359
Sale 24 Jan 2020
Value US$5,964,999.82 | Price 15.69 | Shares 380,256
Planned sale 2 Jan 2020
Value US$122,984.40 | Price 20.50 | Shares 6,000
Planned sale 2 Jan 2020
Value US$187,216.45 | Price 20.50 | Shares 9,133
Planned sale 2 Jan 2020
Value US$256,191.25 | Price 20.50 | Shares 12,500
Sale 24 Dec 2019
Value US$3,319,579.47 | Price 21.95 | Shares 151,233
Sale 24 Dec 2019
Value US$4,362,955.53 | Price 21.95 | Shares 198,767
Sale 23 Dec 2019
Value US$1,235,434.89 | Price 21.83 | Shares 56,595
Sale 23 Dec 2019
Value US$1,623,758.09 | Price 21.83 | Shares 74,384
Sale 20 Dec 2019
Value US$196,296.83 | Price 21.50 | Shares 9,130
Sale 20 Dec 2019
Value US$257,980.90 | Price 21.50 | Shares 11,999
Sale 19 Dec 2019
Value US$118,218.72 | Price 21.68 | Shares 5,454
Sale 19 Dec 2019
Value US$155,370.70 | Price 21.68 | Shares 7,168
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-01 2026-05-28 B Purchase
Xu Diyong
Non-Executive Director Large shareholder
22,388 -15.3%
469.45
US$4,048,021 		22,388 -15.3% 469.45 US$4,048,021
2026-06-01 2026-05-28 B Purchase
Xu Diyong
Non-Executive Director Large shareholder
3,658 +9.9%
140.17
US$3,125,895 		3,658 +9.9% 140.17 US$3,125,895
2026-06-01 2026-05-28 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
7,673 +40.5%
152.25
US$1,393,884 		7,673 +40.5% 152.25 US$1,393,884
2026-06-01 2026-05-28 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
1,250,000 +55.5%
8.00
US$10,000,000 		1,250,000 +55.5% 8.00 US$10,000,000
2026-02-27 2026-02-25 S Sale
2.3
Kalowski Lee

CFO and President

Officer
3,995 -10.0%
4.51
US$18,035 		3,995 -10.0% 4.51 US$18,035
2026-02-27 2026-02-25 S Sale
1.0
Violette Shelia M.

Chief Scientific Officer

Officer
2,815 -4.8%
4.51
US$12,708 		2,815 -4.8% 4.51 US$12,708
2026-02-27 2026-02-25 S Sale
1.5
Morrison Jodie Pope

CEO

Executive Director
9,896 -10.0%
4.51
US$44,675 		9,896 -10.0% 4.51 US$44,675
2025-12-04 2025-12-02 S Sale
2.3
Kalowski Lee

CFO and President

Officer
9,072 -18.5%
3.46
US$31,395 		9,072 -18.5% 3.46 US$31,395
2025-12-04 2025-12-02 S Sale
1.5
Morrison Jodie Pope

CEO

Executive Director
22,506 -18.5%
3.46
US$77,871 		22,506 -18.5% 3.46 US$77,871
2025-12-02 2025-12-02 PrS Proposed sale
1.5
JODIE MORRISON

Officer; Director

Executive Director
22,506
3.46
US$77,871 		22,506 3.46 US$77,871
2025-12-02 2025-12-02 PrS Proposed sale
2.3
LEE KALOWSKI

Officer

Officer
9,072
3.46
US$31,395 		9,072 3.46 US$31,395
2025-08-28 2025-08-26 S Sale
1.5
Morrison Jodie Pope

CEO

Executive Director
10,494 -8.0%
1.80
US$18,900 		10,494 -8.0% 1.80 US$18,900
2025-08-28 2025-08-26 S Sale
2.3
Kalowski Lee

CFO and President

Officer
4,240 -8.0%
1.80
US$7,636 		4,240 -8.0% 1.80 US$7,636
2025-08-28 2025-08-26 S Sale
1.0
Violette Shelia M.

Chief Scientific Officer

Officer
2,990 -4.9%
1.80
US$5,385 		2,990 -4.9% 1.80 US$5,385
2024-08-14 2024-03-25 S Sale
TZIANABOS ARTHUR
Non-Executive Director
265 -3.2%
24.20
US$6,413 		265 -3.2% 24.20 US$6,413
2024-04-23 2024-03-25 PlS Planned sale
Michaud Charles Jr

See Remarks

Officer
75 -7.5%
24.20
US$1,815 		75 -7.5% 24.20 US$1,815
2024-04-23 2024-03-25 PlS Planned sale
Alloway Paul

See Remarks

Officer
268 -9.4%
24.21
US$6,488 		268 -9.4% 24.21 US$6,488
2024-02-15 2024-01-09 PlS Planned sale
TZIANABOS ARTHUR
Non-Executive Director
13,037 -9.2%
0.57
US$7,445 		13,037 -9.2% 0.57 US$7,445
2024-01-05 2024-01-03 PlS Planned sale
Michaud Charles Jr

See Remarks

Officer
1,708 -12.8%
0.57
US$975 		1,708 -12.8% 0.57 US$975
2024-01-05 2024-01-03 PlS Planned sale
Alloway Paul

See Remarks

Officer
7,280 -20.6%
0.57
US$4,120 		7,280 -20.6% 0.57 US$4,120
2023-09-08 2023-09-06 PlS Planned sale
Seymour Albert

See Remarks

Executive Director
1,448 -1.0%
1.15
US$1,665 		1,448 -1.0% 1.15 US$1,665
2023-08-07 2023-08-03 S Sale
2.0
Jordan Julie

Chief Medical Officer

Officer
1,308 -14.9%
1.39
US$1,818 		1,308 -14.9% 1.39 US$1,818
2023-08-07 2023-08-03 PlS Planned sale
2.0
Jordan Julie

Chief Medical Officer

Officer
109 -2.6%
1.39
US$152 		109 -2.6% 1.39 US$152
2023-08-07 2023-08-03 PlS Planned sale
2.0
Jordan Julie

Chief Medical Officer

Officer
436 -10.1%
1.39
US$606 		436 -10.1% 1.39 US$606
2023-08-04 2023-08-02 PlS Planned sale
2.0
Jordan Julie

Chief Medical Officer

Officer
99 -3.5%
1.31
US$130 		99 -3.5% 1.31 US$130
2023-03-06 2023-03-02 PlS Planned sale
Alloway Paul

See Remarks

Officer
10,965 -39.6%
1.45
US$15,863 		10,965 -39.6% 1.45 US$15,863
2023-01-11 2023-01-09 PlS Planned sale
TZIANABOS ARTHUR
Non-Executive Director
10,616 -8.9%
1.39
US$14,762 		10,616 -8.9% 1.39 US$14,762
2023-01-11 2023-01-09 PlS Planned sale
Alloway Paul

See Remarks

Officer
3,090 -13.3%
1.39
US$4,296 		3,090 -13.3% 1.39 US$4,296
2023-01-11 2023-01-09 PlS Planned sale
Blum Michael Lee

Chief Commercial Officer

Officer
2,454 -15.3%
1.39
US$3,412 		2,454 -15.3% 1.39 US$3,412
2023-01-11 2023-01-09 PlS Planned sale
Smith W Bradford

See Remarks

Officer
3,729 -20.8%
1.39
US$5,188 		3,729 -20.8% 1.39 US$5,188
2023-01-11 2023-01-09 PlS Planned sale
Seymour Albert

See Remarks

Executive Director
3,620 -2.5%
1.39
US$5,033 		3,620 -2.5% 1.39 US$5,033
2022-01-12 2022-01-05 PlS Planned sale
Cohn Gabriel

Chief Medical Officer

Officer
1,661 -38.7%
3.78
US$6,279 		1,661 -38.7% 3.78 US$6,279
2022-01-12 2022-01-05 PlS Planned sale
Smith W Bradford

CFO & Treasurer

Officer
2,182 -33.1%
3.78
US$8,248 		2,182 -33.1% 3.78 US$8,248
2022-01-12 2022-01-05 PlS Planned sale
Seymour Albert

Chief Scientific Officer

Officer
1,661 -1.2%
3.78
US$6,279 		1,661 -1.2% 3.78 US$6,279
2022-01-12 2022-01-05 PlS Planned sale
TZIANABOS ARTHUR

President & CEO

Executive Director
5,354 -5.9%
3.78
US$20,239 		5,354 -5.9% 3.78 US$20,239
2022-01-12 2022-01-05 PlS Planned sale
2.9
Kelly Timothy P

Chief Operating Officer

Officer
1,406 -38.7%
3.78
US$5,315 		1,406 -38.7% 3.78 US$5,315
2021-02-09 2021-02-08 PlS Planned sale
Smith W Bradford

CFO & Treasurer

Officer
13,500 -100.0%
14.25
US$192,425 		13,500 -100.0% 14.25 US$192,425
2021-02-05 2021-02-02 PlS Planned sale
2.9
Kelly Timothy P

See Remarks

Officer
500 -100.0%
13.00
US$6,500 		500 -100.0% 13.00 US$6,500
2021-02-03 2021-02-01 PlS Planned sale
2.9
Kelly Timothy P

See Remarks

Officer
4,000 -100.0%
12.37
US$49,460 		4,000 -100.0% 12.37 US$49,460
2021-01-14 2021-01-12 PlS Planned sale
2.9
Kelly Timothy P

See Remarks

Officer
500 -100.0%
13.00
US$6,500 		500 -100.0% 13.00 US$6,500
2021-01-08 2021-01-07 PlS Planned sale
Seymour Albert

Chief Scientific Officer

Officer
5,103 -3.8%
12.05
US$61,469 		5,103 -3.8% 12.05 US$61,469
2021-01-08 2021-01-06 PlS Planned sale
Seymour Albert

Chief Scientific Officer

Officer
9,897 -6.9%
12.06
US$119,395 		9,897 -6.9% 12.06 US$119,395
2021-01-07 2021-01-05 PlS Planned sale
Seymour Albert

Chief Scientific Officer

Officer
10,000 -6.5%
11.44
US$114,422 		10,000 -6.5% 11.44 US$114,422
2021-01-06 2021-01-04 PlS Planned sale
2.9
Kelly Timothy P

See Remarks

Officer
4,000 -100.0%
11.50
US$45,983 		4,000 -100.0% 11.50 US$45,983
2020-12-28 2020-12-22 S Sale
4.0
PARMAR KUSH
Non-Executive Director
20,000 -9.9%
12.82
US$256,400 		20,000 -9.9% 12.82 US$256,400
2020-12-28 2020-12-22 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
20,000 -9.9%
12.82
US$256,400 		20,000 -9.9% 12.82 US$256,400
2020-12-28 2020-12-22 S Sale
4.0
PARMAR KUSH
Non-Executive Director
480,000 -9.9%
12.82
US$6,153,600 		480,000 -9.9% 12.82 US$6,153,600
2020-12-28 2020-12-22 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
480,000 -9.9%
12.82
US$6,153,600 		480,000 -9.9% 12.82 US$6,153,600
2020-12-16 2020-12-14 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
13,703 -6.4%
11.88
US$162,792 		13,703 -6.4% 11.88 US$162,792
2020-12-16 2020-12-14 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
6,297 -2.8%
13.06
US$82,244 		6,297 -2.8% 13.06 US$82,244
2020-12-16 2020-12-14 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
328,862 -6.4%
11.88
US$3,906,881 		328,862 -6.4% 11.88 US$3,906,881
2020-12-16 2020-12-14 S Sale
4.0
PARMAR KUSH
Non-Executive Director
13,703 -6.4%
11.88
US$162,792 		13,703 -6.4% 11.88 US$162,792
2020-12-16 2020-12-14 S Sale
4.0
PARMAR KUSH
Non-Executive Director
6,297 -2.8%
13.06
US$82,244 		6,297 -2.8% 13.06 US$82,244
2020-12-16 2020-12-14 S Sale
4.0
PARMAR KUSH
Non-Executive Director
328,862 -6.4%
11.88
US$3,906,881 		328,862 -6.4% 11.88 US$3,906,881
2020-12-16 2020-12-14 S Sale
3.6
5AM Ventures IV, L.P.
Large shareholder
151,138 -2.8%
13.06
US$1,973,998 		151,138 -2.8% 13.06 US$1,973,998
2020-12-16 2020-12-14 S Sale
4.0
PARMAR KUSH
Non-Executive Director
151,138 -2.8%
13.06
US$1,973,998 		151,138 -2.8% 13.06 US$1,973,998
2020-03-18 2020-03-17 PlS Planned sale
2.9
Kelly Timothy P

See Remarks

Officer
1,315 -100.0%
13.01
US$17,109 		1,315 -100.0% 13.01 US$17,109
2020-02-05 2020-02-03 PlS Planned sale
TZIANABOS ARTHUR

President & CEO

Executive Director
12,500 -13.9%
16.16
US$202,021 		12,500 -13.9% 16.16 US$202,021
2020-02-05 2020-02-03 PlS Planned sale
Smith W Bradford

CFO, Treasurer & Secretary
12,000 -100.0%
16.16
US$193,866 		12,000 -100.0% 16.16 US$193,866
2020-01-31 2020-01-30 S Sale
2.8
Flynn James E
Large shareholder
509,970 -100.0%
15.45
US$7,879,036 		509,970 -100.0% 15.45 US$7,879,036
2020-01-31 2020-01-29 S Sale
2.8
Flynn James E
Large shareholder
8,857 -1.7%
15.45
US$136,808 		8,857 -1.7% 15.45 US$136,808
2020-01-28 2020-01-28 S Sale
2.8
Flynn James E
Large shareholder
65,891 -11.3%
15.51
US$1,021,936 		65,891 -11.3% 15.51 US$1,021,936
2020-01-28 2020-01-27 S Sale
2.8
Flynn James E
Large shareholder
193,359 -24.9%
15.77
US$3,049,600 		193,359 -24.9% 15.77 US$3,049,600
2020-01-28 2020-01-24 S Sale
2.8
Flynn James E
Large shareholder
380,256 -32.8%
15.69
US$5,965,000 		380,256 -32.8% 15.69 US$5,965,000
2020-01-03 2020-01-02 PlS Planned sale
Smith W Bradford

CFO, Treasurer & Secretary
6,000 -100.0%
20.50
US$122,984 		6,000 -100.0% 20.50 US$122,984
2020-01-03 2020-01-02 PlS Planned sale
Seymour Albert

Chief Scientific Officer
9,133 -5.6%
20.50
US$187,216 		9,133 -5.6% 20.50 US$187,216
2020-01-03 2020-01-02 PlS Planned sale
TZIANABOS ARTHUR

President & CEO

Executive Director
12,500 -12.2%
20.50
US$256,191 		12,500 -12.2% 20.50 US$256,191
2019-12-27 2019-12-24 S Sale Flynn James E Large shareholder
151,233 -7.9%
21.95
US$3,319,579 		151,233 -7.9% 21.95 US$3,319,579
2019-12-27 2019-12-24 S Sale Flynn James E Large shareholder
198,767 -7.9%
21.95
US$4,362,956 		198,767 -7.9% 21.95 US$4,362,956
2019-12-23 2019-12-23 S Sale Flynn James E Large shareholder
56,595 -2.9%
21.83
US$1,235,435 		56,595 -2.9% 21.83 US$1,235,435
2019-12-23 2019-12-23 S Sale Flynn James E Large shareholder
74,384 -2.9%
21.83
US$1,623,758 		74,384 -2.9% 21.83 US$1,623,758
2019-12-23 2019-12-20 S Sale Flynn James E Large shareholder
9,130 -0.5%
21.50
US$196,297 		9,130 -0.5% 21.50 US$196,297
2019-12-23 2019-12-20 S Sale Flynn James E Large shareholder
11,999 -0.5%
21.50
US$257,981 		11,999 -0.5% 21.50 US$257,981
2019-12-23 2019-12-19 S Sale Flynn James E Large shareholder
5,454 -0.3%
21.68
US$118,219 		5,454 -0.3% 21.68 US$118,219
2019-12-23 2019-12-19 S Sale Flynn James E Large shareholder
7,168 -0.3%
21.68
US$155,371 		7,168 -0.3% 21.68 US$155,371
Explore more

More insider trading research around Q32 Bio Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America